Novo Nordisk Cuts Forecast Amid Growing Competition
Novo Nordisk (NVO) lowers 2025 guidance for the fourth time as Wegovy and Ozempic sales slow. New CEO battles Eli Lilly competition while pursuing $10B Metsera acquisition.
/ 63 items
#NVO↓
Pfizer's Q3: Profit Boosted by Cost Cuts Amidst Major Obesity Acquisition Battle
Pfizer announced strong third-quarter profits, allowing it to raise its 2025 profit forecast. This improvement relies on major cost-cutting efforts, even as the company faces fierce competition and a high-stakes legal fight over the obesity startup Metsera.
Hims & Hers Shares Jump on Talks With Novo Nordisk, Strong Q3 Results
Hims & Hers Health rose in after-hours trading after revealing talks with Novo Nordisk about offering Wegovy’s new obesity pill. The telehealth firm also beat Q3 revenue estimates, reporting nearly $600 million in sales and strong subscriber growth.
Pfizer Sues Metsera and Novo Nordisk Over Breach of Merger Agreement
Pfizer files lawsuit against Metsera, its board, and Novo Nordisk for breaching a merger agreement, claiming illegal interference and regulatory risks in Novo Nordisk’s proposal.
Eli Lilly Soars on Blockbuster Weight-Loss Drug Sales, Raises 2025 Outlook
Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.
Novo Nordisk Makes $9 Billion Bid for Metsera, Topping Pfizer's Offer
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.